RESUMO
La embolización de la arteria uterina ha sido descrita como un método efectivo y seguro en el tratamiento de los miomas sintomáticos. Se presentan 3 casos de pacientes con útero miomatoso sintomático, y su tratamiento mediante esta técnica. En estos 3 casos, las complicaciones postembolización de los miomas hizo necesaria la práctica de una histerectomía. Así mismo se describen otras complicaciones derivadas de la técnica señaladas en la revisión bibliográfica realizada
Uterine artery embolization has been described as an effective and safe treatment for women with symptomatic uterine leiomyomata. We report three cases of women with symptomatic myomatous uterus and their treatment by this approach. In these three cases, hysterectomy was required due to complications following the embolizations. We also describe other complications of this therapeutic approach that came to light in the literature review
Assuntos
Humanos , Feminino , Adulto , Leiomioma/terapia , Embolização da Artéria Uterina/métodos , Histerectomia/métodos , Doença Granulomatosa Crônica/diagnóstico por imagem , Embolização da Artéria Uterina/efeitos adversos , Resultado do Tratamento , Doença Granulomatosa Crônica/patologiaRESUMO
Objetivo: El carcinoma neuroendocrino de célula pequeña de próstata es una neoplasia infrecuente que supone el 0,5-1% de todas las neoplasias prostáticas. La mediana de supervivencia cáncer-específica de los pacientes con carcinoma neuroendocrino de célula pequeña de próstata es de 19 meses, y el 60,5% de los pacientes presentan enfermedad metastásica. Los factores de transcripción de desarrollo neural son moléculas implicadas en la organogénesis del sistema nervioso central y de precursores neuroendocrinos de diversos tejidos, que incluyen la glándula suprarrenal, el tiroides, el pulmón y la próstata, entre otros órganos. Material y métodos: Presentamos 3 casos de esta infrecuente entidad, aplicando los nuevos criterios de la OMS. Realizamos estudios mediante tinción de H-E y analizamos la expresión de los factores de transcripción de desarrollo neurales Achaete-scute homolog like 1, Thyroid transcription factor 1 y los factores de transcripción clase iii/iv POU, como nueva línea de investigación en la carcinogénesis de los tumores neuroendocrinos de próstata. Resultados: En el caso 1 no se observó inmunoexpresión para TTF1. Los casos 2 y 3 presentaron inmunotinción positiva para ASCL1, e inmunotinción negativa en el caso 1. La inmunotinción para BRN2 fue negativa en el caso 1 y positiva en los casos 2 y 3. Conclusión: Actualmente, la OMS no reconoce ningún marcador molecular ni genético con valor pronóstico. ASCL-1 está relacionado con las vías de señalización NOTCH y WNT. ASCL-1, TTF1 y BRN2 podrían usarse para el diagnóstico precoz y como factor pronóstico y diana terapéutica
Objective: Prostatic small-cell neuroendocrine carcinoma is an uncommon malignancy that constitutes 0.5-1% of all prostate malignancies. The median cancer-specific survival of patients with prostatic small-cell neuroendocrine carcinoma is 19 months, and 60.5% of the patients have metastatic disease. Neural development transcription factors are molecules involved in the organogenesis of the central nervous system and of neuroendocrine precursors of various tissues, including the suprarenal gland, thyroid glands, lungs and prostate. Material and methods: We present 3 cases of this uncommon condition, applying the new World Health Organisation criteria. We conducted studies through haematoxylin and eosin staining and analysed the expression of the neural development transcription factors achaete-scute homolog like 1, thyroid transcription factor 1 and the class III/IV POU transcription factors, as a new research line in the carcinogenesis of prostatic neuroendocrine tumours. Results: In case 1, there was no TTF1 immunoexpression. Cases 2 and 3 had positive immunostaining for ASCL1, and Case 1 had negative immunostaining. BRN2 immunostaining was negative in case 1 and positive in cases 2 and 3. Conclusion: The World Health Organisation does not recognise any molecular or genetic marker with prognostic value. ASCL-1 is related to the NOTCH and WNT signalling pathways. ASCL-1, TTF1 and BRN2 could be used for early diagnosis and as prognostic factors and therapeutic targets
Assuntos
Humanos , Imuno-Histoquímica/métodos , Tumores Neuroendócrinos/patologia , Neoplasias da Próstata/patologia , Marcadores Genéticos , Carcinoma de Células Pequenas/patologia , Fator 3 de Transcrição/análise , Região do Genoma do Complexo Achaete-Scute/genética , Receptores Notch/análise , Transdução de SinaisRESUMO
OBJECTIVE: Prostatic small-cell neuroendocrine carcinoma is an uncommon malignancy that constitutes 0.5-1% of all prostate malignancies. The median cancer-specific survival of patients with prostatic small-cell neuroendocrine carcinoma is 19 months, and 60.5% of the patients have metastatic disease. Neural development transcription factors are molecules involved in the organogenesis of the central nervous system and of neuroendocrine precursors of various tissues, including the suprarenal gland, thyroid glands, lungs and prostate. MATERIAL AND METHODS: We present 3 cases of this uncommon condition, applying the new World Health Organisation criteria. We conducted studies through haematoxylin and eosin staining and analysed the expression of the neural development transcription factors achaete-scute homolog like 1, thyroid transcription factor 1 and the class III/IV POU transcription factors, as a new research line in the carcinogenesis of prostatic neuroendocrine tumours. RESULTS: In case 1, there was no TTF1 immunoexpression. Cases 2 and 3 had positive immunostaining for ASCL1, and Case 1 had negative immunostaining. BRN2 immunostaining was negative in case 1 and positive in cases 2 and 3. CONCLUSION: The World Health Organisation does not recognise any molecular or genetic marker with prognostic value. ASCL-1 is related to the NOTCH and WNT signalling pathways. ASCL-1, TTF1 and BRN2 could be used for early diagnosis and as prognostic factors and therapeutic targets.
Assuntos
Fatores de Transcrição Hélice-Alça-Hélice Básicos/análise , Carcinoma Neuroendócrino/química , Carcinoma de Células Pequenas/química , Proteínas de Ligação a DNA/análise , Proteínas de Homeodomínio/análise , Proteínas de Neoplasias/análise , Fatores do Domínio POU/análise , Neoplasias da Próstata/química , Fatores de Transcrição/análise , Idoso , Biomarcadores Tumorais , Carcinoma Neuroendócrino/genética , Carcinoma de Células Pequenas/genética , Transformação Celular Neoplásica/genética , Amarelo de Eosina-(YS) , Hematoxilina , Humanos , Imuno-Histoquímica , Masculino , Pessoa de Meia-Idade , Prognóstico , Neoplasias da Próstata/genética , Coloração e Rotulagem , Sinaptofisina/análise , Transcrição GênicaRESUMO
OBJETIVO: El nefroma quístico, quiste multilocular o nefroma multilocular quístico, es una neoplasia renal infrecuente, de comportamiento benigno que se descubre habitualmente de formal incidental. MÉTODO: Entre 2010 y 2015, 2 pacientes fueron diagnosticados en nuestro servicio de nefroma quístico. Se revisaron las historias clínicas de dichos pacientes y realizamos una revisión de la literatura sobre las lesiones quísticas renales tanto benignas como malignas. RESULTADO: En este trabajo presentamos dos nuevos casos correspondientes a dos mujeres de 75 y 33 años que fueron intervenidas con sospecha de neoplasia renal. CONCLUSIONES: El tratamiento de elección del nefroma quístico es la cirugía y el diagnóstico final es anatomopatológico. En el manejo de estas lesiones, es preciso hacer el diagnóstico diferencial con neoplasias renales malignas como el carcinoma renal quístico multilocular y el nefroblastoma quístico
OBJECTIVE: Multicystic nephroma (multilocular cystic nephroma, multilocular cyst) is a relatively rare benign neoplasm of the kidney. Most patients are asymptomatic and tumours are usually discovered incidentally. METHODS: Between 2010 and 2015, 2 patients with cystic nephroma at our institution were diagnosed and treated. Our study includes two new cases of cystic nephroma and a review of the literature about the differential diagnosis of a cystic renal mass. RESULTS: In this report we present two cases of multilocular cystic nephroma in a 75-year-old-female and a 33-year-old female. They were diagnosed clinically as a renal mass and surgery was performed. CONCLUSIONS: Surgery is the main treatment for cystic nephroma. The combination of clinical, biochemical and radiological features may help in lesion characterization but only histology can provide the definite diagnosis. The differential diagnosis includes multilocular cystic renal cell carcinoma and cystic nephroblastoma
Assuntos
Humanos , Feminino , Adulto , Idoso , Carcinoma de Células Renais/metabolismo , Carcinoma de Células Renais/patologia , Dor Abdominal/patologia , Neoplasias Renais/metabolismo , Adenoma Oxífilo/metabolismo , Queratinas/administração & dosagem , Carcinoma de Células Renais/complicações , Carcinoma de Células Renais/diagnóstico , Dor Abdominal/complicações , Neoplasias Renais/patologia , Adenoma Oxífilo/patologia , Queratinas/provisão & distribuiçãoRESUMO
OBJECTIVE: Multicystic nephroma (multilocular cystic nephroma, multilocular cyst) is a relatively rare benign neoplasm of the kidney. Most patients are asymptomatic and tumours are usually discovered incidentally. METHODS: Between 2010 and 2015, 2 patients with cystic nephroma at our institution were diagnosed and treated. Our study includes two new cases of cystic nephroma and a review of the literature about the differential diagnosis of a cystic renal mass. RESULTS: In this report we present two cases of multilocular cystic nephroma in a 75-year-old-female and a 33-year-old female. They were diagnosed clinically as a renal mass and surgery was performed. CONCLUSIONS: Surgery is the main treatment for cystic nephroma. The combination of clinical, biochemical and radiological features may help in lesion characterization, but only histology can provide the definite diagnosis. The differential diagnosis includes multilocular cystic renal cell carcinoma and cystic nephroblastoma.